Iron homeostasis during cystic fibrosis pulmonary exacerbation

Clinical and Translational Science

Volumn 5, Issue 4, 2012, Pages 368-373

  Gifford, Alex H ^a   Moulton, Lisa A ^a   Dorman, Dana B ^a   Olbina, Gordana ^b   Westerman, Mark ^b   Parker, H Worth ^a   Stanton, Bruce A ^c   O'Toole, George A ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Intrinsic LifeSciences LLC   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cystic fibrosis; Exacerbation; Hepcidin; Interleukin 6; Iron

Indexed keywords

ANTIBIOTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; HEPCIDIN; HEPCIDIN 25; INTERLEUKIN 6; IRON; UNCLASSIFIED DRUG;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CYSTIC FIBROSIS; DISEASE EXACERBATION; ERYTHROPOIESIS; FEMALE; FORCED EXPIRATORY VOLUME; HEMOGLOBIN BLOOD LEVEL; HOMEOSTASIS; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; MALE; PRIORITY JOURNAL; SPUTUM LEVEL; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CYSTIC FIBROSIS; DISEASE PROGRESSION; ERYTHROPOIETIN; FEMALE; FORCED EXPIRATORY VOLUME; HEMOGLOBINS; HOMEOSTASIS; HUMANS; INTERLEUKIN-6; IRON; MALE; MIDDLE AGED; SPUTUM; WEIGHT GAIN; YOUNG ADULT;

EID: 84864960247     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2012.00417.x     Document Type: Article

References (33)

1. Abbott J, Holt A, Hart A, Morton AM, MacDougall L, Pogson M, Milne G, Rodgers HC, Conway SP. What defines a pulmonary exacerbation? The perceptions of adults with cystic fibrosis. J Cyst Fibros. 2009; 8: 356-359.
2. Flume PA, Mogayzel PJ, Jr., Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009; 180: 802-808.
3. de Boer K, Vandemheen KL, Tullis E, Doucette S, Fergusson D, Freitag A, Paterson N, Jackson M, Lougheed MD, Kumar V, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011; 66: 680-685.
4. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34: 91-100.
5. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010; 182: 627-632.
6. Moreau-Marquis S, Stanton BA, O'Toole GA. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm Pharmacol Ther. 2008; 21: 595-599.
7. Moreau-Marquis S, Bomberger JM, Anderson GG, Swiatecka-Urban A, Ye S, O'Toole GA, Stanton BA. The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol. 2008; 295: L25-L37.
8. Stites SW, Walters B, O'Brien-Ladner AR, Bailey K, Wesselius LJ. Increased iron and ferritin content of sputum from patients with cystic fibrosis or chronic bronchitis. Chest. 1998; 114: 814-819.
9. Reid DW, Lam QT, Schneider H, Walters EH. Airway iron and iron-regulatory cytokines in cystic fibrosis. Eur Respir J. 2004; 24: 286-291.
10. Gray RD, Duncan A, Noble D, Imrie M, O'Reilly DS, Innes JA, Porteous DJ, Greening AP, Boyd AC. Sputum trace metals are biomarkers of inflammatory and suppurative lung disease. Chest. 2010; 137: 635-641.
11. Reid DW, Carroll V, O'May C, Champion A, Kirov SM. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. Eur Respir J. 2007; 30: 286-292.
12. Andrews NC. Iron Deficiency and Related Disorders. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means, Jr.RT, eds: Wintrobe's Clinical Hematology. Philadelphia, PA: Lippincott Williams & Wilkins; 2009, 810-833.
13. Anderson GJ, Frazier DM, McLaren GD. Iron absorption and metabolism. Curr Opin Gastroenterol. 2009; 25: 129-135.
14. Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol. 2011; 64: 281-286.
15. Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, Zoller H, Bellmann-Weiler R, Niederegger H, Talasz H, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008; 111: 2392-2399.
16. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271-1276.
17. Gifford AH, Miller SD, Jackson BP, Hampton TH, O'Toole GA, Stanton BA, Parker HW. Iron and CF-related anemia: expanding clinical and biochemical relationships. Pediatr Pulmonol. 2011; 46: 160-165.
18. Reid DW, Withers NJ, Francis L, Wilson JW, Kotsimbos TC. Iron deficiency in cystic fibrosis: relationship to lung disease severity and chronic Pseudomonas aeruginosa infection. Chest. 2002; 121: 48-54.
19. Keevil B, Rowlands D, Burton I, Webb AK. Assessment of iron status in cystic fibrosis patients. Ann Clin Biochem. 2000; 37: 662-665.
20. Bainton DF, Finch CA. The Diagnosis of Iron Deficiency Anemia. Am J Med. 1964;37: 62-70.
21. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum -hepcidin. Blood. 2008; 112: 4292-4297.
22. McCormick J, Green MW, Mehta G, Culross F, Mehta A. Demographics of the UK cystic fibrosis population: implications for neonatal screening. Eur J Hum Genet. 2002; 10: 583-590.
23. Collaco JM, Green DM, Cutting GR, Naughton KM, Mogayzel PJ, Jr. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med. 2010; 182: 1137-1143.
24. Termoz A, Touzet S, Bourdy S. Effectiveness of home treatment for patients with cystic fibrosis: the intravenous administration of antibiotics to treat respiratory infections. Pediatr Pulmonol. 2008; 43: 908-915.
25. Modi AC, Lim CS, Driscoll KA, Piazza-Waggoner C, Quittner AL, Wooldridge J. Changes in pediatric health-related quality of life in cystic fibrosis after IV antibiotic treatment for pulmonary exacerbations. J Clin Psychol Med Settings. 2010; 17: 49-55.
26. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2010 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2011, p. 50.
27. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010; 33: 2697-2708.
28. Pond MN, Morton AM, Conway SP. Functional iron deficiency in adults with cystic fibrosis. Respir Med. 1996; 90: 409-413.
29. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med. 1998; 157: 1764-1769.
30. Lamont IL, Konings AF, Reid DW. Iron acquisition by Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. Biometals. 2009; 22: 53-60.
31. Dale JC, Ruby SG. Specimen collection volumes for laboratory tests. Arch Pathol Lab Med. 2003; 127: 162-168.
32. Thavendiranathan P, Bagai A, Ebidia A, Detsky AS, Choudhry NK. Do blood tests cause anemia in hospitalized patients? The effect of diagnostic phlebotomy on hemoglobin and hematocrit levels. J Gen Intern Med. 2005; 20: 520-524.
33. Wisser D, van Ackern K, Knoll E, Wisser H, Bertsch T. Blood loss from laboratory tests. Clin Chem. 2003; 49: 1651-1655.